Related by context. All words. (Click for frequent words.) 68 metastatic colorectal 67 novel tubulin binding 67 metastatic bladder 67 recurrent NSCLC 67 anthracyclines taxanes 67 gemcitabine carboplatin 67 metastatic squamous cell carcinoma 66 estramustine 66 HRPC 66 sorafenib Nexavar 66 SCCHN 66 dasatinib Sprycel ® 66 taxane chemotherapy 66 cisplatin chemotherapy 66 HER2 positive metastatic breast 66 recurrent metastatic 66 EGFR expressing mCRC 66 Fludarabine 66 platinum refractory 66 systemic ALCL 66 Amrubicin 66 metastatic pancreatic 65 fallopian tube carcinoma 65 TTF Therapy 65 receptor tyrosine kinase inhibitor 65 recurrent squamous cell carcinoma 65 stage IIIb IV 65 recurrent glioblastoma multiforme 65 metastatic breast 65 Diffuse Large B 65 BRCA deficient 65 gefitinib Iressa 65 papillary renal cell carcinoma 65 gemcitabine chemotherapy 65 zalutumumab 65 blood clot dissolving 65 taxane refractory 65 sunitinib malate 65 metastatic relapsed 64 Aplidin 64 potent triglyceride lowering 64 chemoradiotherapy 64 dasatinib Sprycel 64 trastuzumab Herceptin ® 64 Vidaza azacitidine 64 metastatic gastric 64 mRCC 64 Pemetrexed 64 Cloretazine R 64 LHRH receptor positive 64 carboplatin paclitaxel 64 refractory CTCL 64 depsipeptide 64 EGFR mutation positive 64 metastatic GIST 64 sunitinib Sutent 64 anthracycline taxane 64 MAGE A3 ASCI 64 metastatic malignant 64 Cloretazine 64 Cloretazine ® 64 refractory colorectal cancer 64 cetuximab Erbitux R 64 CYT# potent vascular disrupting 64 CA4P 63 metastatic medullary thyroid 63 refractory metastatic 63 refractory indolent non 63 acute myeloid 63 metastatic malignant melanoma 63 refractory cutaneous T 63 stage IIIB 63 bevacizumab Avastin ® 63 cytotoxic chemotherapy 63 Aflibercept 63 metastatic CRC 63 paclitaxel carboplatin 63 VNP#M 63 unresectable locally advanced 63 nonmetastatic 63 Doxil ® 63 heavily pretreated patients 63 Surgical resection 63 tumor vascular disrupting 63 ZACTIMA 63 lenalidomide Revlimid R 63 acute leukemias 63 evaluating Xcytrin 63 colorectal cancer liver metastases 63 Sudhir Agrawal D.Phil 63 leukemia AML 63 chemotherapeutic regimen 63 relapsed MM 63 glufosfamide 63 EGFR TKI 63 ® lenalidomide 63 Nexavar sorafenib 63 thymoma 63 ELACYT 63 refractory ovarian cancer 63 tumors GIST 63 HGS ETR2 63 Tarceva TM 63 neoadjuvant treatment 63 etoposide 63 GRN# 63 lymphoma CTCL 63 imatinib therapy 63 nilotinib Tasigna ® 63 Xelox 63 Seliciclib 63 docetaxel chemotherapy 62 resistant ovarian cancer 62 MGd 62 alkylating agent 62 erlotinib Tarceva ® 62 temsirolimus 62 assessing T DM1 62 multiple myeloma MM 62 Enzastaurin 62 IV metastatic melanoma 62 EGFR tyrosine kinase inhibitor 62 Vicinium TM 62 docetaxel Taxotere ® 62 metastatic renal cell carcinoma 62 PNP inhibitor 62 Proxinium TM 62 refractory multiple myeloma 62 Panzem NCD 62 doublet chemotherapy 62 gastrointestinal stromal 62 cell lymphoma CTCL 62 EGFr expressing metastatic colorectal 62 previously untreated follicular 62 CLL SLL 62 cediranib 62 gastrointestinal stromal tumor GIST 62 pamidronate 62 refractory chronic lymphocytic 62 polycythemia vera essential thrombocythemia 62 fluoropyrimidine 62 cyclophosphamide chemotherapy 62 oral anti arrhythmic 62 metastatic SCCHN 62 advanced metastatic renal 62 mitoxantrone plus 62 Fludara 62 Irinotecan 62 NMIBC 62 alkylating agents 62 Hodgkin lymphoma HL 62 anti muscarinic 62 recurrent malignant glioma 62 hepatocellular carcinoma HCC 62 Troxatyl 62 systemic anaplastic large 62 FUSILEV enhances 62 heavily pretreated 62 mCRC patients 62 histone deacetylase HDAC inhibitor 62 anastrazole 62 refractory NSCLC 62 axitinib 62 imatinib Gleevec 62 5 fluorouracil leucovorin 62 Omacetaxine 62 relapsed refractory AML 62 anthracycline containing 62 vinca alkaloid 62 unresectable 62 FOLFOX6 62 malignant ascites 62 IgG1 monoclonal antibody 62 BAY #-# 62 antibody MAb 62 prostate cancer HRPC 62 galiximab 61 gemtuzumab ozogamicin 61 palliative radiotherapy 61 chemoradiation therapy 61 taxane resistant 61 EndoTAGTM 1 61 prior chemotherapy regimens 61 aflibercept VEGF Trap 61 Hepatocellular Carcinoma HCC 61 acute GvHD 61 cancer mCRC 61 refractory gastrointestinal stromal 61 metastatic renal 61 corticosteroid dexamethasone 61 sorafenib tablets 61 anti leukemic 61 IAP inhibitor 61 opioid induced constipation OIC 61 liposomal doxorubicin 61 Adjuvant chemotherapy 61 hepatic metastases 61 bevacizumab Avastin 61 samalizumab 61 neurologic progression 61 ganetespib 61 taxane chemotherapy administered 61 pancreatic adenocarcinoma 61 metastatic RCC 61 lymphoid malignancies 61 pain palliation 61 relapsing remitting MS RRMS 61 mTOR mammalian target 61 carcinoma mCRC 61 BCG refractory 61 castrate resistant 61 docetaxel Taxotere R 61 hormone refractory metastatic prostate 61 cutaneous T 61 IL# PE#QQR 61 gemcitabine Gemzar 61 taxane therapy 61 prostate carcinoma 61 ErbB2 positive 61 gemcitabine cisplatin 61 Akt activation 61 mycophenolate mofetil 61 pancreatic carcinoma 61 bortezomib Velcade R 61 adjuvant radiotherapy 61 Tyrima 61 lymphomas leukemias 61 bleomycin 61 systemic antifungal 61 overlapping toxicities 61 neoadjuvant therapy 61 advanced unresectable 61 metastatic colorectal cancer 61 myelodysplastic myeloproliferative diseases 61 oral clodronate 61 thalidomide Thalomid 61 radiation sensitizer 61 metastatic androgen independent 61 epithelial tumors 61 metastatic CRPC 61 evaluating T DM1 61 seliciclib 61 phase IIb study 61 cisplatin gemcitabine 61 Phase #b/#a clinical 61 non squamous NSCLC 61 anthracycline chemotherapy 61 unresectable stage 61 Mitomycin C 61 nonsmall cell lung cancer 61 Cytoxan 61 gastrointestinal stromal tumors GIST 61 pheochromocytoma 61 Annamycin 61 adriamycin 61 ixabepilone 61 stage chemoresistant ovarian 61 tyrosine kinase inhibitors TKIs 61 IV NSCLC 61 advanced hepatocellular carcinoma 60 interferon ribavirin 60 castrate resistant prostate cancer 60 thetreatment 60 plus prednisone 60 mapatumumab 60 hormone refractory prostate cancer 60 relapsed ovarian cancer 60 farletuzumab 60 alpha folate receptor 60 relapsed multiple myeloma 60 standard chemotherapy regimen 60 irinotecan containing 60 refractory acute myeloid 60 carcinoma HCC 60 Tarceva erlotinib 60 Hormone Refractory Prostate Cancer 60 neoadjuvant chemotherapy 60 trastuzumab Herceptin R 60 Cloretazine R VNP#M 60 humanised monoclonal antibody 60 vinflunine 60 dexanabinol 60 acetonide FA 60 differentiated thyroid 60 Stage IIIB IV 60 capecitabine Xeloda R 60 cetuximab Erbitux 60 Folfox 60 Trabectedin 60 irinotecan doxorubicin oxaliplatin paclitaxel 60 Cutaneous T 60 mTOR inhibitors 60 medullary thyroid cancer 60 metastatic renal cell 60 pegylated interferon peg IFN 60 IMiDs ® compound 60 BCIRG 60 chemotherapy cisplatin 60 evaluating picoplatin 60 hormone LHRH antagonist 60 Peginterferon alfa 2b 60 inotropic 60 Gleevec imatinib mesylate 60 adalimumab Humira 60 Rituxan rituximab 60 histologies 60 5 FU leucovorin 60 Apaziquone 60 potent antiproliferative 60 Refractory Hodgkin Lymphoma 60 fulvestrant 60 HGS ETR1 60 HER2 positive cancers 60 imatinib Gleevec ® 60 cetuximab Erbitux ® 60 portal vein thrombosis 60 Onyx Pharmaceuticals Bayer HealthCare 60 pertuzumab 60 psychiatric disorders ATI 60 indolent NHL 60 acute promyelocytic leukemia APL 60 epithelial ovarian 60 CHOP chemotherapy 60 AVASTIN 60 clodronate 60 Xeloda ® 60 Voreloxin 60 novel VDA molecule 60 haematologic malignancies 60 paclitaxel Taxol R 60 Phase III randomized controlled 60 Bevacizumab Avastin 60 eribulin mesylate 60 ara C 60 metastatic carcinoma 60 MKC# PP 60 romidepsin 60 Kinoid 60 resistant hormone refractory 60 small lymphocytic lymphoma 60 Ceflatonin 60 paclitaxel cisplatin 60 gastrointestinal stromal tumor 60 EOquin TM 60 Li Fraumeni Syndrome 60 hepatocellular cancer 60 Neoadjuvant 60 #mg BID [001] 60 equivocal appendicitis 60 nab paclitaxel 60 cinacalcet 60 parathyroid carcinoma 60 indolent follicular non 60 TELCYTA 60 HER2 + 60 cytoreductive nephrectomy 60 Zarnestra 60 fibrinolytic 60 follicular Non Hodgkin 60 relapsed refractory multiple myeloma 60 epirubicin 60 advanced epithelial ovarian 60 paclitaxel Taxol 60 pancreatic islet cell 60 Cabazitaxel 59 cutaneous T cell 59 nilotinib 59 BRIM2 59 idarubicin 59 clinically localized prostate 59 minimally symptomatic 59 relapsed refractory 59 metastatic castrate resistant 59 MYLOTARG 59 sorafenib Nexavar ® 59 cytotoxic therapy 59 distant metastasis 59 Erbitux cetuximab 59 5FU 59 Xanafide 59 metastatic HRPC 59 oral ridaforolimus 59 Carfilzomib 59 ALK inhibitor 59 histological subtype 59 Acute Myeloid Leukaemia AML 59 alfa 2a 59 KIACTA ™ 59 III antiarrhythmic 59 Waldenstrom macroglobulinemia 59 5-FU/LV 59 phase Ib 59 plus prednisone prednisolone 59 Bevacizumab 59 aflibercept 59 Glioblastoma Multiforme 59 atypical Hemolytic Uremic Syndrome 59 imetelstat 59 Vandetanib 59 erlotinib Tarceva 59 ELOXATIN 59 #I TM# 59 untreated de novo 59 mertansine 59 Fludara ® 59 azacytidine 59 intratumoral injection 59 abiraterone acetate 59 sunitinib 59 metastatic hormone refractory 59 HNSCC 59 unique alkylating agent 59 chemotherapy docetaxel 59 anti atherothrombotic 59 intravesical infusion therapy 59 cabazitaxel 59 prostate cancer CRPC 59 TNF antagonist 59 Triapine R 59 androgen deprivation 59 cytoreduction 59 INSPIRE Trial Phase III 59 Metastatic Colorectal Cancer 59 fallopian tube cancers 59 Subgroup analysis 59 neratinib 59 hematological cancers 59 multi kinase inhibitor 59 chemo radiotherapy 59 oblimersen 59 RhuDex R 59 potentially hepatotoxic 59 metastatic NSCLC 59 IMiDs R 59 SNT MC# 59 MabThera Rituxan 59 biliary tract cancer 59 relapsed CLL 59 Pathway Inhibitor 59 eritoran 59 refractory metastatic colorectal cancer 59 trabectedin 59 remission induction 59 relapsed mantle 59 AEG# 59 riociguat 59 radiolabeled TM# 59 NSCLC 59 concurrent chemoradiation 59 postoperative chemotherapy 59 Mitoxantrone 59 Telcyta 59 CEQ# 59 hematopoietic cancers 59 Panzem R NCD 59 superficial bladder cancer 59 small molecule tyrosine 59 Torisel 59 injectable urethral bulking 59 antiresorptive 59 Soft Tissue Sarcoma 59 HuMax EGFr 59 HSP# inhibitor 59 OMP #M# 59 gemcitabine Gemzar ® 59 Nicole Onetto MD 59 topotecan 59 HER2 negative 59 Relapsed Refractory 59 dexpramipexole 59 paclitaxel poliglumex 59 colorectal carcinoma 59 TACE 59 relapsed SCLC 59 platelet inhibitor 59 MabCampath 59 antifibrinolytic 59 debulking surgery 59 TNF blocking 59 locoregional recurrence 59 acute myelogenous leukemia AML 59 malignant pleural mesothelioma 59 alvespimycin 59 Phase 1b clinical trials 59 Ceflatonin R 59 capecitabine Xeloda 59 Phase #/#a trial 59 Epidermal Growth Factor Receptor 59 Advanced Renal Cell 59 colorectal adenocarcinoma 59 adjuvant cisplatin 59 chemoresistant 59 anti angiogenic agents 59 androgen independent 59 non metastatic osteosarcoma 59 cisplatin carboplatin 59 rALLy clinical trial 59 syngeneic 59 dexamethasone Decadron 59 essential thrombocythemia ET 59 HQK 59 FOLFIRI 59 plus gemcitabine 59 cyclophosphamide methotrexate 59 motesanib 59 cholangiocarcinoma 59 LUX Lung 58 vinorelbine 58 PKC# 58 liver resection 58 FOLFOX chemotherapy 58 Degarelix 58 sorafenib Nexavar R 58 Sanofi Aventis Taxotere 58 induces apoptosis 58 MDS AML 58 Ixempra 58 dacarbazine DTIC 58 Genasense ® 58 antimetabolite 58 CTAP# Capsules 58 combretastatin A4 phosphate CA4P 58 situ CIS 58 liposomal formulation 58 Telintra 58 histone deacetylase inhibitor 58 B CLL 58 KRAS mutant 58 PDX pralatrexate 58 non squamous 58 irinotecan chemotherapy 58 prostate adenocarcinoma 58 gastroesophageal junction 58 elacytarabine 58 ribavirin therapy 58 YONDELIS 58 BRAF inhibitor 58 Philadelphia Chromosome Positive 58 APOPTONE 58 randomized Phase IIb 58 Amgen Neulasta ® 58 huN# DM1 58 non splenectomized 58 metastatic colorectal carcinoma 58 allogeneic transplantation 58 talabostat 58 Talabostat 58 FOLFOX4 58 Crohn disease CD 58 Cotara ® 58 Allovectin 7 ® 58 Xcytrin 58 HER2 overexpression 58 methotrexate therapy 58 BCG refractory carcinoma 58 EGFr 58 weekly subcutaneous injections 58 invasive bladder 58 Velcade bortezomib 58 refractory AML 58 pomalidomide 58 genotypic resistance 58 posaconazole 58 cisplatin vinorelbine 58 regorafenib 58 Onrigin 58 Gleevec imatinib 58 de novo kidney transplant 58 bladder ovarian 58 baseline LDH 58 enzastaurin 58 ovarian carcinoma 58 tyrosine kinase inhibitor 58 brivaracetam 58 Dacogen decitabine 58 microtubule targeting 58 myeloproliferative disorders 58 ZOLINZA 58 tiuxetan 58 Everolimus 58 obatoclax 58 chemotherapeutic drug 58 factor TNF 58 OvaRex MAb 58 colorectal lung 58 preoperative chemotherapy 58 peritumoral brain edema 58 DOXIL 58 vandetanib 58 chronic idiopathic thrombocytopenic purpura 58 reteplase 58 PREZISTA r 58 Trastuzumab 58 cisplatin resistant 58 metaglidasen 58 refractory myeloma 58 colorectal liver 58 Alessandro Riva 58 multicenter Phase II 58 cervical carcinoma 58 Immunosuppressive 58 allogeneic bone marrow 58 SYN# 58 neuropathy sparing 58 basiliximab 58 pediatric acute lymphoblastic 58 standard chemotherapy regimens 58 squamous non 58 including eniluracil ADH 58 severe oral mucositis 58 Cremophor 58 pemetrexed 58 metastatic kidney 58 metastatic HER2 negative 58 unresectable liver cancer 58 radiotherapeutic 58 amrubicin 58 tyrosine kinase inhibitor TKI 58 stage IIIb 58 carcinoid tumors 58 #mg QD [001] 58 recurrent ovarian cancer 58 LymphoStat B belimumab 58 infusional 5-FU/LV 58 pancreatic colon 58 atrial fibrillation budiodarone ATI 58 ThermoDox R 58 relapsed myeloma 58 GW# [003] 58 selectively inhibited 58 microtubule inhibitor 58 temozolomide TMZ 58 VELCADE melphalan 58 Smac mimetic 58 unresectable tumors 58 bendamustine 58 cis retinoic acid 58 insulin sensitizing 58 Revlimid lenalidomide 58 Myelodysplastic Syndrome MDS 58 anthracycline therapy 58 Gleevec resistant 58 Bortezomib 58 bevacizumab Avastin R 58 CIMZIA TM certolizumab pegol 58 mTOR inhibitor 58 plus 5-FU/LV 58 Epratuzumab 58 pediatric malignancies 58 myelofibrosis MF 58 Epirubicin 58 Taxotere docetaxel 58 Arranon 58 HGS ETR1 mapatumumab 58 vascular disrupting agent 58 advanced carcinoid 58 polycythemia vera PV 58 hereditary medullary thyroid 58 kidney urologic 58 node metastases 58 azacitidine 58 recurrent glioblastoma 58 Yondelis ® 58 Cannabinor 58 non resectable 58 Gorlin syndrome 58 vemurafenib 58 Chronic Lymphocytic Leukemia CLL 58 Tanespimycin 58 vinca alkaloids 58 Anti angiogenic 58 Lubiprostone 58 Her2 positive 58 GEM OS1 58 progressive metastatic prostate 58 HGS# 58 haematologic 58 denileukin diftitox 58 non splenectomised 58 cyclophosphamide Cytoxan 58 Recurrent Chest Wall 58 endocrine therapies 58 cardiotoxic 58 huC# DM4 58 cytostatic 58 advanced metastatic prostate 58 Tavocept 58 IMC A# 58 TKI therapy 58 chronic lymphocytic leukemia CLL 58 pegylated liposomal doxorubicin 58 deep venous thromboses 58 verteporfin 58 low dose cytarabine 58 peritoneal carcinomatosis 58 Denufosol 58 Dacogen injection 58 lung pancreatic 58 targeting CD# 58 histologically confirmed 57 TroVax ® 57 myeloproliferative disorder 57 intravesical 57 Pertuzumab 57 PI3K/Akt pathway inhibitor 57 immune modulating 57 midstage clinical 57 T#I [002] 57 BN# [004] 57 advanced NSCLC 57 metastatic castration resistant 57 K ras mutations 57 mutated KRAS gene 57 refractory peripheral T 57 hepatorenal syndrome 57 EGFR tyrosine kinase inhibitors 57 TRAIL induced apoptosis 57 anti neoplastic 57 relapsed leukemia 57 Bosutinib 57 Orally administered 57 docetaxel Taxotere 57 CTEPH 57 IV tPA 57 IGFBP 3 57 Torisel temsirolimus 57 Herceptin trastuzumab 57 KRAS wild 57 hematological malignancies 57 leukemia CLL 57 resectable pancreatic cancer 57 oral chemotherapeutic agent 57 Cell Lymphoma 57 potent anticancer 57 Navelbine ® 57 taxane 57 Perifosine 57 Leukemias 57 Golimumab 57 metastatic ovarian cancer 57 TRO# 57 PAOD 57 phase IIb clinical 57 sodium thiosulfate STS 57 Millennium Velcade 57 TMEM density 57 Glufosfamide 57 antitumor activity 57 KRAS mutant tumors 57 adecatumumab 57 underwent surgical resection 57 induced anemia 57 nonmyeloablative 57 fosbretabulin 57 Myelodysplastic Syndrome 57 fluorouracil 57 Myelodysplastic syndromes MDS 57 chemotherapy regimens 57 SUTENT 57 malignant pleural mesothelioma MPM 57 proteasome inhibitor 57 untreated multiple myeloma 57 multikinase inhibitor 57 rhIGFBP 3 57 secondary hyperparathyroidism 57 entinostat 57 bortezomib Velcade 57 adjuvant radiation 57 Acute myeloid leukemia 57 sodium glucose cotransporter 57 tumor xenograft models 57 IGF IR 57 neoplasias 57 cervical lymph nodes 57 cilengitide 57 Crizotinib 57 castration resistant hormone refractory 57 bevacizumab Avastin Genentech 57 gastrointestinal stromal tumors 57 IRESSA 57 AML acute myeloid 57 myelodysplastic syndromes MDS 57 treatment naive genotype 57 follicular lymphoma FL 57 Bezielle 57 Brentuximab Vedotin SGN 57 Fluorouracil 57 TLR8 agonist 57 forodesine 57 blastic phase 57 antithymocyte globulin 57 immunotherapeutic agent 57 nilotinib Tasigna 57 resectable 57 sargramostim 57 paclitaxel chemotherapy 57 essential thrombocythemia 57 AVOREN 57 Anthracycline 57 ribavirin RBV 57 prednisone prednisolone 57 small molecule Hedgehog 57 PSMA ADC 57 hematologic toxicity 57 tenecteplase 57 HSCT 57 Blinatumomab 57 squamous cell lung cancer 57 Temsirolimus 57 AKT inhibitor 57 neck squamous cell 57 chemopreventive agent 57 olaparib 57 neuroendocrine cancers 57 Nexavar tablets 57 chemotherapeutic regimens 57 Ozarelix 57 GRNOPC1 contains 57 biologic therapy 57 stage IIIB IV 57 Phase Ib II 57 Cetuximab Erbitux 57 Taxotere ® 57 5 Fluorouracil 57 pancreatic prostate 57 Pfizer Sutent 57 Aurora kinase 57 lumiliximab 57 apoptosis inducer 57 paclitaxel Taxol ® 57 immunomodulatory therapy 57 Ocrelizumab 57 alkylating 57 oral antiviral 57 iniparib 57 liver metastases 57 operable breast cancer 57 Anaplastic 57 Sapacitabine 57 Circulating tumor cells 57 acadesine 57 xenograft models 57 mutated KRAS 57 cytarabine daunorubicin 57 Virulizin ® 57 targeted radiotherapeutic 57 Immunohistochemical staining 57 chronic myeloid 57 patients receiving myelosuppressive 57 receiving highly emetogenic 57 monoclonal antibody conjugated 57 YONDELIS R 57 dacarbazine 57 Mantle Cell Lymphoma 57 signal transduction inhibitors 57 chemotherapeutic agent 57 ofatumumab HuMax CD# 57 biochemical relapse 57 Hycamtin ® 57 oral Hycamtin 57 cytotoxic therapies 57 non hodgkin lymphoma 57 TO AVOID PREGNANCY WHILE 57 chimeric monoclonal antibody 57 poly ADP ribose polymerase 57 ON #.Na 57 olmesartan 57 inhibit angiogenesis 57 radiation chemoradiation 57 soft tissue sarcomas 57 prospectively defined 57 TNF blocker therapy 57 Caelyx 57 interferon beta therapy 57 mutated K ras 57 mitomycin 57 orally administered inhibitor 57 efaproxiral 57 osteoporotic vertebral compression fractures 57 protein kinase inhibitor 57 dasatinib 57 nucleoside analog 57 sunitinib Sutent ® 57 recurrent prostate cancer 57 gadolinium contrast 57 evaluating tivozanib 57 Platinol ® cisplatin 57 5 HT4 57 chemoresistance 57 advanced nonsquamous NSCLC 57 EOquin TM phase 57 ERBB2 57 DAPT 57 smoldering multiple myeloma 57 nodal metastasis 57 PARP inhibitor 57 TREANDA 57 Pegylated Interferon 57 Atrasentan 57 unresectable recurrent 57 RSR# 57 VEGF receptor 57 Sutent sunitinib 57 Lenalidomide 57 FluCAM 57 Allovectin 7 57 apremilast 57 MGCD# [001] 57 iniparib BSI 57 castration resistant prostate cancer 57 receptor blocker 57 leukemia myeloma 57 investigational antiviral 57 afatinib 57 Stage IIIb 57 Elitek 57 transitional cell carcinoma 57 PXD# 57 FOLPI 57 inhibits Akt activation 57 imatinib resistant 57 Bayer HealthCare Onyx Pharmaceuticals 57 raloxifene Evista 57 Valproic acid 57 Ribavirin causes 57 CALGB # [002] 57 Azacitidine 57 CPOP R 57 CINTREDEKIN BESUDOTOX 57 chemoembolization 57 allogeneic hematopoietic stem cell 57 leukemia APL 57 neoadjuvant 57 Campath ® 57 Cytarabine 57 XYOTAX TM 57 albumin bound paclitaxel 57 FOLFOX6 chemotherapy regimen 57 malignant lymphomas 56 refractory prostate cancer 56 ZD# [001] 56 antiangiogenic agent 56 mg kg dose 56 HCV RESPOND 2 56 paragangliomas 56 novel anticancer 56 completely resected 56 untreated CLL 56 Bcr Abl T#I mutation 56 phosphate binding 56 dose escalation Phase 56 flutamide 56 doxorubicin cyclophosphamide 56 Alemtuzumab 56 Vincristine 56 chronic ITP patients 56 Cell Lymphoma CTCL 56 Roche Xeloda 56 fibrinolysis 56 irbesartan 56 renal cell carcinoma 56 BRAF V#E mutation 56 oral COTI 56 EGFR HER2 56 Folotyn 56 TORISEL 56 Zorbtive TM 56 OPAXIO 56 Temodar ® 56 selective inhibition 56 luteinizing hormone releasing 56 FOLFIRI chemotherapy 56 curative resection 56 locoregional 56 haematological malignancies 56 TYKERB 56 lipid modifying 56 bosutinib 56 rALLy 56 baminercept 56 refractory chronic myeloid 56 perioperatively 56 selective modulator 56 HRPC ovarian cancer 56 cirrhosis liver failure 56 squamous cell carcinoma SCC 56 humanized interleukin 6 56 rapid virologic response 56 STRIDE PD 56 metastatic neuroendocrine tumors 56 hematological malignancy 56 p# biomarker 56 Vinorelbine 56 Toxicities 56 OXi# 56 BR.# 56 mycophenolate mofetil MMF 56 metastatic dermatofibrosarcoma protuberans DFSP 56 alpha 2a